+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma

British Journal of Cancer 92(9): 1754-1758
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
Enhancer of zeste homologue 2 (EZH2), a member of the polycomb group protein family, plays a crucial role in the regulation of embryonic development and has been associated with the regulation of the cell cycle. Recently, several studies have shown that EZH2 is highly expressed in aggressive tumours, including human breast cancer, prostate cancer, and lymphomas. We thus analysed EZH2 expression using real-time reverse transcription - polymerase chain reaction, and correlated its expression status with various clinicopathological parameters in 66 patients with hepatocellular carcinoma (HCC). We found high expression of EZH2 in human liver cancer cell lines. Furthermore, EZH2 gene-expression levels in tumour tissue specimens (0.34 +/- 0.52) were significantly higher (P<0.0001) than those in the corresponding nontumour tissue specimens (0.07 +/- 0.09). The incidence of cancer cell invasion into the portal vein was significantly higher (P<0.001) in the high EZH2 expression group ( 26 of the 33, 79%) than in the low expression group ( 13 of the 33, 39%). However, there was no significant difference in the disease-free survival rate between the two groups. The findings of this study indicate that EZH2 mRNA expression was upregulated in human HCC and may play an important role in tumour progression, especially by facilitating portal vein invasion.

(PDF same-day service: $19.90)

Accession: 011867206

PMID: 15856046

DOI: 10.1038/sj.bjc.6602531

Related references

Clinicopathological significance of EZH2 and Bmi 1 expression in patients with hepatocellular carcinoma. 2007

Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Journal of Cancer Research and Clinical Oncology 141(4): 661-669, 2015

Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 51(2): 204-218, 2007

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma. Virchows Archiv 464(4): 463-471, 2014

KIAA0101 mRNA expression in the peripheral blood of hepatocellular carcinoma patients: Association with some clinicopathological features. Clinical Biochemistry 49(10-11): 787-791, 2016

Prognostic and clinicopathological significance of MACC1 expression in hepatocellular carcinoma patients: a meta-analysis. International Journal of Clinical and Experimental Medicine 8(4): 4769-4777, 2015

Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Digestive and Liver Disease 40(7): 560-567, 2008

c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Research 33(8): 3241-3245, 2013

UbcH10 expression in hepatocellular carcinoma and its clinicopathological significance. Nan Fang Yi Ke Da Xue Xue Bao 31(2): 280-284, 2012

Expression and clinicopathological significance of GRAMD4 in hepatocellular carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 29(2): 190-193, 2014